Boston Scientific (BSX)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-15

$44.39+0.57%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Boston Scientific’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.9%

+10% or more+5%0%−5%−10% or less

3.42 → 3.39 EPS · FY ending Dec 31, 2027 · 15 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 15; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cardiovascular segment grows at least 10% annually	Boston Scientific grows sales about 8% a year with strong cardiovascular gains.	Broken	Cardiovascular segment growth falls below 7% next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Cardiovascular segment revenue increased from $3.085 billion in 2025-Q1 to $3.624 billion in 2026-Q2, showing strong double-digit growth in 2025 and solid growth in 2026. Management's focus on cardiovascular innovation and clinical trials aligns with this sustained growth, indicating delivery on this priority. Delivery assessment Oct 15, 2026
Net sales grow at least 7% annually	A primary condition in Boston Scientific's published investment case. The stated target is >=7% YoY revenue growth.	Intact	YoY revenue growth falls below 5% next year	Revenue growth: 7.53% FY2026-Q2; GAAP. Published target: >=7% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Aug 3, 20267.528156 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f6db4b02-9f83-45dd-a40e-21ca4471a694. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Revenue grew from $4.663 billion in 2025-Q1 to $5.442 billion in 2026-Q2, representing consistent double-digit growth in 2025 and mid-single-digit growth in 2026. Management has consistently emphasized net sales growth and the trajectory is delivering with sustained operational and organic increases. Delivery assessment Oct 15, 2026
Improve operational efficiency through cost management	A supporting condition in Boston Scientific's published investment case. The stated target is Operational efficiency improves steadily.	Intact	No improvement in operational efficiency metrics over next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating margin near 13.5%	Profit margins stay near 13.5%.	Intact	Operating margin falls below 12% next year	Operating margin: 21.65% FY2026-Q2; GAAP. Published target: ~13.5% operating margin. Target period is not explicitly aligned with this observation. Source published Aug 3, 202621.646454 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f6db4b02-9f83-45dd-a40e-21ca4471a694. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$3.39

$3.71 → $3.39 · observed estimates

FY2027 revenue$22.22B

$23.32B → $22.22B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.71	$23,323,652,430	26 / 28
2026-07-25	$3.71	$23,323,652,430	26 / 28
2026-07-26	$3.71	$23,323,652,430	26 / 28
2026-07-27	$3.71	$23,323,652,430	26 / 28
2026-07-28	$3.71	$23,323,652,430	26 / 28
2026-07-29	$3.71	$23,294,282,120	27 / 29
2026-07-30	$3.71	$23,294,282,120	27 / 29
2026-07-31	$3.48	$22,439,461,310	27 / 29
2026-08-01	$3.48	$22,439,461,310	27 / 29
2026-08-02	$3.48	$22,439,461,310	27 / 29
2026-08-03	$3.44	$22,344,771,660	27 / 29
2026-08-04	$3.44	$22,344,771,660	27 / 29
2026-08-05	$3.44	$22,336,796,680	27 / 29
2026-08-06	$3.44	$22,336,796,680	27 / 29
2026-08-07	$3.43	$22,287,352,201	16 / 22
2026-08-08	$3.44	$22,336,808,840	27 / 29
2026-08-09	$3.44	$22,336,808,840	27 / 29
2026-08-10	$3.44	$22,336,808,840	27 / 29
2026-08-11	$3.43	$22,287,352,201	16 / 22
2026-08-12	$3.44	$22,336,808,840	27 / 29
2026-08-13	$3.43	$22,287,352,201	16 / 22
2026-08-14	$3.43	$22,287,352,201	16 / 22
2026-08-15	$3.43	$22,287,352,201	16 / 22
2026-08-16	$3.43	$22,287,352,201	16 / 22
2026-08-17	$3.43	$22,287,352,201	16 / 22
2026-08-18	$3.43	$22,287,352,201	16 / 22
2026-08-19	$3.43	$22,287,352,201	16 / 22
2026-08-20	$3.43	$22,287,352,201	16 / 22
2026-08-21	$3.43	$22,287,352,201	16 / 22
2026-08-22	$3.42	$22,280,030,158	16 / 22
2026-08-23	$3.42	$22,280,030,158	16 / 22
2026-08-24	$3.42	$22,280,030,158	16 / 22
2026-08-25	$3.42	$22,280,030,158	16 / 22
2026-08-26	$3.42	$22,280,030,158	16 / 22
2026-08-27	$3.42	$22,280,030,158	16 / 22
2026-08-28	$3.42	$22,280,030,158	16 / 22
2026-08-29	$3.42	$22,280,030,158	16 / 22
2026-08-30	$3.42	$22,280,021,279	16 / 22
2026-08-31	$3.42	$22,280,021,279	16 / 22
2026-09-01	$3.42	$22,280,021,279	16 / 22
2026-09-02	$3.42	$22,280,021,279	16 / 22
2026-09-03	$3.42	$22,280,021,279	16 / 22
2026-09-04	$3.42	$22,277,378,422	16 / 22
2026-09-05	$3.42	$22,277,378,422	16 / 22
2026-09-06	$3.42	$22,277,378,422	16 / 22
2026-09-07	$3.42	$22,277,378,422	16 / 22
2026-09-08	$3.42	$22,277,378,422	16 / 22
2026-09-09	$3.42	$22,277,378,422	16 / 22
2026-09-10	$3.42	$22,247,140,637	16 / 22
2026-09-11	$3.42	$22,247,140,637	16 / 22
2026-09-12	$3.42	$22,247,140,637	16 / 22
2026-09-13	$3.42	$22,247,140,637	16 / 22
2026-09-14	$3.42	$22,247,140,637	16 / 22
2026-09-15	$3.42	$22,247,140,637	16 / 22
2026-09-16	$3.41	$22,242,506,659	16 / 22
2026-09-17	$3.41	$22,242,506,659	16 / 22
2026-09-18	$3.41	$22,242,506,659	16 / 22
2026-09-19	$3.41	$22,242,506,659	16 / 22
2026-09-20	$3.41	$22,229,578,087	16 / 22
2026-09-21	$3.41	$22,227,362,200	16 / 22
2026-09-22	$3.41	$22,209,612,200	16 / 22
2026-09-23	$3.41	$22,209,612,200	16 / 22
2026-09-24	$3.41	$22,209,612,200	16 / 22
2026-09-25	$3.40	$22,198,862,200	16 / 22
2026-09-26	$3.40	$22,187,651,486	16 / 22
2026-09-27	$3.40	$22,187,651,486	16 / 22
2026-09-28	$3.40	$22,187,651,486	16 / 22
2026-09-29	$3.40	$22,187,651,486	16 / 22
2026-09-30	$3.40	$22,187,651,486	16 / 22
2026-10-01	$3.40	$22,187,651,486	16 / 22
2026-10-02	$3.40	$22,178,990,772	16 / 22
2026-10-03	$3.40	$22,179,007,811	15 / 21
2026-10-04	$3.40	$22,178,990,772	15 / 21
2026-10-05	$3.40	$22,178,990,772	15 / 21
2026-10-06	$3.39	$22,225,133,629	15 / 21
2026-10-07	$3.39	$22,225,133,629	15 / 21
2026-10-08	$3.39	$22,225,133,629	15 / 21
2026-10-09	$3.39	$22,225,133,629	15 / 21
2026-10-10	$3.39	$22,225,133,629	15 / 21
2026-10-11	$3.39	$22,223,597,914	15 / 21
2026-10-12	$3.39	$22,223,597,914	15 / 21
2026-10-13	$3.39	$22,223,610,839	15 / 21
2026-10-14	$3.39	$22,223,603,979	15 / 21
2026-10-15	$3.39	$22,215,403,979	15 / 21

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	32	4
2026-06-01	28	4
2026-07-01	28	5
2026-08-01	27	5
2026-09-01	26	6
2026-10-01	26	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 26 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades4 maintains

Recent actions · Sep 16–Oct 15 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Truist FinancialOct 14 · prior Jul 16

$62.00 → $51.00-17.7%

Mizuho SecuritiesOct 13 · prior Jul 15

$70.00 → $55.00-21.4%

BarclaysOct 6 · prior May 28

$89.00 → $48.00-46.1%

BernsteinOct 3

$54.00New observation · no comparable prior

Wells FargoSep 23 · prior Jul 30

$50.00 → $48.00-4.0%

OppenheimerSep 21 · prior Jul 27

$85.00 → $65.00-23.5%

$0$48.95$97.90

0 raises · 5 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cardiovascular segment grows at least 10% annuallyPublished status: Broken
Net sales grow at least 7% annuallyRevenue growth: 7.53%
Improve operational efficiency through cost managementDirect metric needs a verified mapping
Operating margin near 13.5%Operating margin: 21.65%

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-60.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Boston Scientific outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on long-term growth, particularly in the cardiovascular segment. The current thesis state indicates that while recent performance is strong, the management's volatility and external economic factors present challenges.

What's priced into Boston Scientific

The market has priced BSX as a cheap option compared to its peers, reflecting a low expectations gap. However, there is a fragility due to weak execution quality, which suggests that the stock's current valuation may not fully account for potential risks.

What the fundamentals likely do

Management is on track with priorities like driving net sales growth and expanding the cardiovascular segment, which have shown strong results. However, there is a near-term risk of missing earnings expectations, especially given the recent history of misses in the industry.

What Boston Scientific hinges on

The long-term thesis hinges on the company's ability to maintain sales growth and manage its operational execution effectively. Additionally, external factors such as sector performance and economic indicators like job reports will significantly influence BSX's trajectory.